Last month, the FDA published a long awaited report on biomedical innovation, their only course of defense in the recent onslaught against the agency. Historically, the FDA has played a significant role in the protection of our health, assuming sole responsibility for the approval of medical products, but it appears that congressional confidence in the agency is waning.
Alzheimer’s is the only top 10 killer disease in the U.S. that cannot be prevented, cured or even treated effectively over time. One big barrier: there are not enough volunteers for experimental drug trials for Alzheimer’s disease.
Scientists at the New York Stem Cell Foundation Laboratory have done what scientists do best: they have narrowed the question. By creating cells capable of growing into any cell type in the human body, research is moving us beyond fear mongering over cloning technologies to study these cells as potential weapons against Alzheimer’s, Parkinson’s, diabetes and other medical maladies.
On June 26, 2011 I was interviewed by BioCentury This Week to share the Alliance for Aging Research’s impressions on the fifth reauthorization of the Food and Drug Administration’s Prescription Drug User Fee program. Thanks to Congress, we and other active patient groups were able to lend an early voice in helping to shape how user fees might be used to help speed the delivery of better treatments and cures to patient in need of relief from Alzheimer’s, Cancer, Parkinson’s and many more diseases.
This is one of the best articles on Alzheimer's I’ve seen to date. It is written by Don C. Reed, a stem cell activist in California, on the promise of current research, and on embryonic stem cells; bringing attention to a subject that is often forgotten and underfunded.
Twenty-five years ago a young lawyer fresh out of Harvard’s Kennedy School of Government came to a fledgling group called the Aging Research Policy Council volunteering free legal services. But first he needed support for pro bono work from his firm’s senior partner, Sargent Shriver.
It seems Dr. Carl Elliott has let his instincts as a provocateur get the better of his perspective as a physician and healer. Promoting his book "White Coat, Black Hat: Adventures on the Dark Side of Medicine,” Dr. Elliott, a frequent contributor to The New Yorker and Atlantic Monthly, finds it deplorable that physicians who use drugs to relieve human misery have any actual contact with companies that research, develop and sell those medicines.